MONDAY, June 2, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic solution) for the treatment of signs and symptoms of dry eye disease.

Currently, dry eye disease treatment options are limited due to slow therapeutic onset, patient dissatisfaction, and poor adherence. Tryptyr works by stimulating corneal sensory nerves to rapidly increase natural tear production. The ophthalmic solution will be available in single-dose vials with a recommended dosage of one drop in each eye twice a day.